| pubmed-article:7503961 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7503961 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:7503961 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7503961 | lifeskim:mentions | umls-concept:C0085112 | lld:lifeskim |
| pubmed-article:7503961 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:7503961 | lifeskim:mentions | umls-concept:C0017007 | lld:lifeskim |
| pubmed-article:7503961 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:7503961 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:7503961 | pubmed:dateCreated | 1993-12-23 | lld:pubmed |
| pubmed-article:7503961 | pubmed:abstractText | The effect of weekly gamma-globulin injection on the development of human B-cell tumors was studied in 120 mice with severe combined immunodeficiency (SCID). The mice were injected intraperitoneally (i.p.) with human peripheral mononuclear cells (PBMC) from 6 different Epstein-Barr virus (EBV)-seropositive donors. Animals repopulated with cells from 5 donors received gamma-globulin or saline for 20 weeks and were followed up to 24 weeks after reconstitution. A delay in the appearance of fata EBV-derived human B-cell tumors was noticed in the gamma-globulin-treated groups as compared to the controls. In a separate experiment, the effect of gamma-globulin treatment during the initial 4 weeks after reconstitution was compared to treatment from week 5 to week 8 as well as to a continuous 20-week treatment. The results from this experiment showed that B-cell tumor growth could be prevented just as efficiently when the animals were treated only during the first 4 weeks. In contrast, no preventive effect was seen when the first gamma-globulin dose was given at the beginning of week 5 after reconstitution. Our results indicate that gamma-globulin reduces the frequency of EBV-derived B-cell tumor development and suggest that SCID mice repopulated with human cells represent a useful in vivo model for evaluation of the prophylactic and/or therapeutic effects of immunomodulatory treatments in lympho-proliferative disorders associated with immunosuppression. | lld:pubmed |
| pubmed-article:7503961 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7503961 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7503961 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7503961 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7503961 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7503961 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7503961 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7503961 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7503961 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7503961 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:7503961 | pubmed:author | pubmed-author:HammarströmLL | lld:pubmed |
| pubmed-article:7503961 | pubmed:author | pubmed-author:SmithC ICI | lld:pubmed |
| pubmed-article:7503961 | pubmed:author | pubmed-author:ChristenssonB... | lld:pubmed |
| pubmed-article:7503961 | pubmed:author | pubmed-author:AbediM RMR | lld:pubmed |
| pubmed-article:7503961 | pubmed:author | pubmed-author:al-MasudSS | lld:pubmed |
| pubmed-article:7503961 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7503961 | pubmed:day | 11 | lld:pubmed |
| pubmed-article:7503961 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:7503961 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7503961 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7503961 | pubmed:pagination | 824-9 | lld:pubmed |
| pubmed-article:7503961 | pubmed:dateRevised | 2007-7-24 | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:meshHeading | pubmed-meshheading:7503961-... | lld:pubmed |
| pubmed-article:7503961 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:7503961 | pubmed:articleTitle | Gamma-globulin modulates growth of EBV-derived B-cell tumors in SCID mice reconstituted with human lymphocytes. | lld:pubmed |
| pubmed-article:7503961 | pubmed:affiliation | Department of Clinical Immunology, Huddinge Hospital, Karolinska Institute, Sweden. | lld:pubmed |
| pubmed-article:7503961 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7503961 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7503961 | lld:pubmed |
